Lightcast aims to unleash new capabilities within the single-cell analysis field by developing a more accessible, scalable, and flexible platform for scientists in basic, translational, and applied research. These capabilities will empower new biological discoveries and accelerate the development of novel drugs, therapies, and biologics. Founded in 2019 and based in Cambridge, UK, Lightcast has invented a technology that uses rays of light to control picoliter-scale droplets for functional analysis of individual cells.
Lightcast
- Life Sciences
- Cambridge, United Kingdom
- £20m
- lightcast.bio
- Update Information
More venture news
- 29 Jul 2026

QureightQureight lands £15m Series B led by Molten Ventures to bring AI imaging to clinical trials for lung and heart disease
Series BLife Sciences - 7 Jul 2026

Healome TherapeuticsHealome Therapeutics raises £2m to advance eye-drop matrix technology treating dry eye and ocular surface disease
SeedLife Sciences - 6 Jul 2026

Revolver TherapeuticsRevolver Therapeutics raises £600k in funding led by QantX to develop peptides that shut down cancer-driving proteins
EquityLife Sciences
